CN1062656A - The preparation technology of canceration shutoff agent " zengshengping tablet " - Google Patents
The preparation technology of canceration shutoff agent " zengshengping tablet " Download PDFInfo
- Publication number
- CN1062656A CN1062656A CN 90109821 CN90109821A CN1062656A CN 1062656 A CN1062656 A CN 1062656A CN 90109821 CN90109821 CN 90109821 CN 90109821 A CN90109821 A CN 90109821A CN 1062656 A CN1062656 A CN 1062656A
- Authority
- CN
- China
- Prior art keywords
- preparation technology
- cortex dictamni
- standby
- extractum
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 238000005516 engineering process Methods 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000003902 lesion Effects 0.000 claims abstract description 6
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940126678 chinese medicines Drugs 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 239000002893 slag Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 abstract description 7
- 210000000981 epithelium Anatomy 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 206010020880 Hypertrophy Diseases 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 230000036952 cancer formation Effects 0.000 abstract description 2
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000001093 anti-cancer Effects 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000002386 leaching Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- 239000010808 liquid waste Substances 0.000 description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000005619 esophageal carcinoma Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A kind of preparation technology of Chinese traditional compound medicine of barrier treatment of precancerous lesion.Primary raw material all has Chinese medicine anticancer and the anti-cancer effect by Six-element to be formed, and becomes extractum through the extraction with aqueous solution effective ingredient, makes different dosage form then and forms.Through experiment of rat and dog and 2531 routine epithelium of esophagus severe hypertrophy patients' observation, the result shows, " zengshengping tablet " is a kind of tumor prevention agent of safe, effective, the novel blocking-up carcinogenesis that has no side effect.
Description
The invention belongs to the medicament preparation method.
The esophageal carcinoma is one of China's tumor occurred frequently, and annual death rate occupies second of national malignant tumor.The hypertrophy that experiment showed, the generation of the esophageal carcinoma and epithelium of esophagus is very close, and the severe hypertrophy of epithelium of esophagus is the precancerous lesion of esophagus.Therefore, manage to block or treat the severe hypertrophy of epithelium of esophagus, promptly become important measures of the prevention esophageal carcinoma.Yet the measure that drug application blocking-up precancerous lesion changes to cancer still belongs to blank at home and abroad.
Summary of the invention:
The present invention is a Chinese traditional compound medicine, and (W/W) is as follows for its percentage composition:
Rhizoma Dioscoreae Bulbiferae 3-6 Spica Prunellae 18-25
Rhizoma Bistortae 17-21 Herba Patriniae 17-23
Radix Sophorae Tonkinensis 18-24 Cortex Dictamni 8-12
Getting Cortex Dictamni powder, to be broken into fine powder standby.All the other Chinese medicine of the five flavours are all put in the container, add suitable quantity of water, decoct 2 hours, and filtering liquid medicine, medicinal residues add suitable quantity of water again, decoct leaching medicinal liquid waste 1.5 hours.The medicinal liquid that merges secondary, being evaporated to relative density is that 1.20-1.45(50 ℃ of heat is surveyed) extractum.At last with standby Cortex Dictamni fine powder and concentrated extract uniform mixing, add an amount of excipient and make various dosage forms as tablet, coated tablet, electuary, capsule, powder or liquid etc.
The toxicity of " zengshengping tablet " and clinical effectiveness
1. acute toxicity testing: oral this medicine of mice 20g/kg(is equivalent to 286 times of people's dosage every day), secondary was observed for two weeks and was not had dead every day.Can not ask the LD50 of oral dose with Miller and TainterShi method, belong to utmost point low toxicity material.
2. long term toxicity test: with 80 of 14 of normal dogs and rat, oral " zengshengping tablet " 2g/kg and 10g/kg observe half a year respectively.Do not find unusual at aspects such as sign, activity, appetite and growths of dog and rat.Blood phase, routine urinalysis, liver, renal function and electrocardiogram are all normal.The histopathologic examination of 12 main organs such as the heart, liver, spleen, lung, kidney, brain, all no abnormal or damage.
3. human body observation of curative effect: to suffering from epithelium of esophagus severe outgrowth 2531 routine patients, carried out the barrier treatment of esophageal precancerous lesion, every day oral " zengshengping tablet " 2.4g(8 sheet), the 3-5 that takes medicine has carried out the esophageal cytology check then.The result shows that " zengshengping tablet " can make the outgrowth cancer rate of epithelium of esophagus severe descend 52.2% and 47.3% respectively, with matched group the difference of highly significant is arranged, and demonstrates " zengshengping tablet " and esophageal precancerous lesion is had certainly and blocks curative effect significantly.
In a word, by zoopery and on-the-spot anthroposcopy, " zengshengping tablet " is a kind of tumor prevention medicine of novel blocking-up carcinogenesis of safe, effective, nontoxic pair effect.
Embodiment 1
Get Cortex Dictamni 210g, it is standby to be ground into fine powder.Get each 420g of Rhizoma Dioscoreae Bulbiferae 100g, Radix Sophorae Tonkinensis, Herba Patriniae, Rhizoma Bistortae and Spica Prunellae again, insert in the container, it is an amount of to add water, decocts 2 hours, and leaching medicinal liquid, medicinal residues add an amount of water again, decocts leaching medicinal liquid waste 1.5 hours.Twice filtrate is merged, is evaporated to 1.30 to 1.35(50 ℃ of heat of relative density and surveys) extractum.With standby Cortex Dictamni fine powder and spissated extractum uniform mixing, add excipient at last, be pressed into the 0.3g sheet and get final product.
Embodiment 2
Get Cortex Dictamni 230g, it is standby to be ground into fine powder.Get Rhizoma Dioscoreae Bulbiferae 120g, Radix Sophorae Tonkinensis 480g, Herba Patriniae 400g, Rhizoma Bistortae and each 420g of Spica Prunellae again, insert in the container, it is an amount of to add water, decocts 2 hours, and leaching medicinal liquid, medicinal residues add suitable quantity of water again, decocts leaching medicinal liquid waste 1.5 hours.Twice filtrate is merged, is evaporated to relative density 1.20-1.45(50 ℃ of heat and surveys) extractum.With standby Cortex Dictamni fine powder and spissated extractum uniform mixing, add an amount of excipient and make electuary at last.
Embodiment 3
Get Cortex Dictamni 150g, it is standby to be ground into fine powder.Get Rhizoma Dioscoreae Bulbiferae 60g, Radix Sophorae Tonkinensis 360g, Herba Patriniae 340g, Rhizoma Bistortae 340g and Spica Prunellae 360g again, insert in the container, it is an amount of to add water, decocts 2 hours, and leaching medicinal liquid, medicinal residues add suitable quantity of water again, decocts leaching medicinal liquid waste 1.5 hours.Twice filtrate is merged, is evaporated to relative density 1.30-1.35(50 ℃ of heat and surveys) extractum.With standby Cortex Dictamni fine powder and spissated extractum uniform mixing, add an amount of excipient at last, be pressed into coated tablet and get final product.
Claims (5)
1, a kind of preparation technology of blocking treatment medicine of precancerous lesion is characterized in that pulverizing the Chinese medicine Cortex Dictamni standby.All the other Chinese medicines decoct with water, remove slag, medicinal liquid is condensed into extractum, with standby Cortex Dictamni fine powder and extractum mixing, make certain dosage form then.(W/W) is composed as follows for its percentage:
Rhizoma Dioscoreae Bulbiferae 3-6 Spica Prunellae 18-25
Rhizoma Bistortae 17-21 Herba Patriniae 17-23
Radix Sophorae Tonkinensis 18-24 Cortex Dictamni 8-12
2, preparation technology according to claim 1, it is standby to it is characterized in that Cortex Dictamni is all ground into fine powder.
3, preparation technology according to claim 1 is characterized in that all the other Chinese medicine of the five flavours are placed in the container, adds suitable quantity of water, decocts twice, and 2 hours for the first time, 1.5 hours for the second time, filter and remove residue merged medicinal liquid twice.
4, preparation technology according to claim 1 is characterized in that medicinal liquid is that 1.20-1.45(50 ℃ of heat is surveyed through being evaporated to relative density) extractum.
5, preparation technology according to claim 1 is characterized in that the standby fine powder and the concentrated extract uniform mixing of Cortex Dictamni are added an amount of excipient and make dosage forms such as coated tablet, tablet, electuary, capsule, powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 90109821 CN1062656A (en) | 1990-12-20 | 1990-12-20 | The preparation technology of canceration shutoff agent " zengshengping tablet " |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 90109821 CN1062656A (en) | 1990-12-20 | 1990-12-20 | The preparation technology of canceration shutoff agent " zengshengping tablet " |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1062656A true CN1062656A (en) | 1992-07-15 |
Family
ID=4881622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 90109821 Pending CN1062656A (en) | 1990-12-20 | 1990-12-20 | The preparation technology of canceration shutoff agent " zengshengping tablet " |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1062656A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940696A (en) * | 2010-09-10 | 2011-01-12 | 天津康晨瑞信医药集团有限公司 | Method for preparing Chinese medicinal compound Zengshengping |
| CN101966272A (en) * | 2009-10-21 | 2011-02-09 | 天津康晨瑞信医药集团有限公司 | Chinese medicinal composition for treating proliferative diseases |
| CN102114164A (en) * | 2011-03-01 | 2011-07-06 | 天津康晨瑞信医药集团有限公司 | Application of traditional Chinese medicine preparation in treating oral leukoplakia and preventing diseases caused by oral leukoplakia canceration |
-
1990
- 1990-12-20 CN CN 90109821 patent/CN1062656A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966272A (en) * | 2009-10-21 | 2011-02-09 | 天津康晨瑞信医药集团有限公司 | Chinese medicinal composition for treating proliferative diseases |
| CN101940696A (en) * | 2010-09-10 | 2011-01-12 | 天津康晨瑞信医药集团有限公司 | Method for preparing Chinese medicinal compound Zengshengping |
| CN101940696B (en) * | 2010-09-10 | 2012-08-22 | 天津康晨瑞信医药集团有限公司 | Method for preparing Chinese medicinal compound Zengshengping |
| CN102114164A (en) * | 2011-03-01 | 2011-07-06 | 天津康晨瑞信医药集团有限公司 | Application of traditional Chinese medicine preparation in treating oral leukoplakia and preventing diseases caused by oral leukoplakia canceration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5589182A (en) | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression | |
| DE3328262C2 (en) | ||
| AU9764498A (en) | Galenic preparation for prevention and treatment of hepatocarcinoma | |
| KR100671432B1 (en) | Herb composition for asthma maintenance therapy | |
| CN101569739B (en) | Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof | |
| CN100448460C (en) | Herbal drug composition for cartilage protection | |
| CN113813347A (en) | Preparation method and process of compound paclitaxel anti-tumor capsule tablet | |
| KR20190076102A (en) | A Pharmaceutical composition comprising mixed herbal extract for enhancing the effect of anti-cnacer drug | |
| CN116370556B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, tonifying qi and soothing nerves and preparation method thereof | |
| CN112656877A (en) | Pharmaceutical composition for treating cervical disc herniation and preparation method and application thereof | |
| CN1062656A (en) | The preparation technology of canceration shutoff agent " zengshengping tablet " | |
| CN100464759C (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| Choudhury et al. | Estimation of the anti-proliferative potential of Costus pictus on MOLT-4 human cancer cell line | |
| CN104825644B (en) | Chinese medicinal preparation for treating leukemia | |
| CN1399999A (en) | Medicine for curing malignant turnor and its preparation method | |
| CN101199652B (en) | Medicament for treating acute, subacute eczema and preparing method thereof | |
| CN101496869B (en) | Chinese medicine preparation for treating bronchitis | |
| CN101653488A (en) | Application of Chinese medicinal composition in preparation of medicament for resisting myocardial stunning | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| AU2020103366A4 (en) | Traditional Chinese medicine composition for treating liver cancer and preparation method thereof | |
| Ali | Comparative Evaluation of Diuretic Activity of Ethanolic Extracts of (Celery) Apium graveolens and (Parsley) Petroselinum crispum in Male Rats | |
| CN114073740B (en) | Preparation method of dripping pills for regulating qi and activating blood circulation | |
| CN1124634A (en) | Antitussive Chinese drug and preparing process thereof | |
| CN111759949B (en) | Traditional Chinese medicine composition for treating large intestine melanosis and preparation method thereof | |
| CN1161852A (en) | Aikeping-medicine for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |